ESMO GYNAECOLOGICAL CANCERS CONGRESS 2025
Atezolizumab added to chemotherapy and bevacizumab is effective regardless of PD-L1 status in untreated recurrent and metastatic cervical cancer
An analysis of the BEATcc trial showed that PD-L1 is not a robust biomarker for response to treatment
Relacorilant added to nab-paclitaxel prolongs progression-free survival in platinum-resistant ovarian cancer
The ROSELLA trial highlights the efficacy and tolerability of the combination even in patients with a poorer prognosis
An analysis reveals distinct patterns of expression of antibody–drug conjugate targets in high-grade serous ovarian cancer
A small Japanese study provides useful insights on determining the role of these agents in cancer care, but studies in larger, more diverse populations are needed
LATEST NEWS
Experts recommend limiting germline genetic testing for breast cancer to seven genes
Newly-released ESMO recommendations critically assess specific germline pathogenic variants in terms of cancer-related mortality and testing implications for patients and their families
Study findings support a growing shift towards “personalised de-escalation” treatment strategies in anal and rectal cancer care
Reduced-dose chemoradiotherapy and non-surgical strategies show promising outcomes with fewer long-term side-effects in lower gastrointestinal cancers
Tucatinib combo continues to show durable benefit in HER2-mutated metastatic breast cancer
Final data from the SGNTUC-019 trial support the use of the agent with trastuzumab in heavily pretreated patients
Promising early results for emiltatug ledadotin in heavily pretreated triple-negative breast cancer
Phase 1 trial data highlights preliminary efficacy and manageable safety of B7-H4–targeted antibody-drug conjugate in women receiving at least one prior topoisomerase-1 ADC
TILs show value in predicting relapse risk in TNBC
Retrospective data suggest that patients with low baseline TILs and nodal involvement have poor prognosis despite achieving pathological complete response
Tailored use of chemotherapy may benefit some early-stage ER+/HER2– breast cancers
Results from two studies suggest that withholding chemotherapy for some patients may not impact efficacy, but an understanding of clinical and biological features is paramount
AI & DIGITAL ONCOLOGY
Will voice-enabled AI have a role in oncology?
Progress in artificial intelligence tools is opening-up novel modalities to provide education and doctor-patient communication
Will AI reshape breast cancer screening?
While AI tools have shown promise in reducing false positives and aiding radiologists, large prospective trials are now exploring how technology should be integrated in screening programmes
AI is transforming cancer diagnosis, but systemic barriers still hold it back
A new ESMO systematic review maps AI’s growing role in pathology and oncology, as well as challenges in its implementation due to infrastructure, regulatory framework and human factors
OPINIONS
Advancing perioperative treatment in resectable non-small cell lung cancer
Marina Chiara Garassino
Early data presented for a biomarker-guided care of metastatic hormone-sensitive prostate cancer
Elena Castro
Challenging ageism in gynaecological cancers
Elene Mariamidze
The emerging era of liquid biopsy in endocrine-resistant metastatic breast cancer
Philippe Aftimos
First-line use of antibody-drug conjugates: a turning point in metastatic breast cancer
Paolo Tarantino
OPINIONS
Advancing perioperative treatment in resectable non-small cell lung cancer
Marina Chiara Garassino
Early data presented for a biomarker-guided care of metastatic hormone-sensitive prostate cancer
Elena Castro
Challenging ageism in gynaecological cancers
Elene Mariamidze
The emerging era of liquid biopsy in endocrine-resistant metastatic breast cancer
Philippe Aftimos
First-line use of antibody-drug conjugates: a turning point in metastatic breast cancer
Paolo Tarantino